Opinion: FDA peptide policy risks undermining drug development and patient safety
Last week, the Department of Health and Human Services took the bold step of allowing the compounding of six unapproved peptide products. There are several reasons why this is a…
DO
By Daniel Okafor · Regulatory Correspondent
Nov 2 12:23 ETSource: BioSpace
From the source
Read at biospace.comOpinion: FDA peptide policy risks undermining drug development and patient safety
Last week, the Department of Health and Human Services took the bold step of allowing the compounding of six unapproved peptide products. There are several reasons why this is a bad idea.
